Racial Disparities in Nephrectomy and Mortality Among Patients with Renal Cell Carcinoma: Findings from SEER

Purpose To assess racial differences in the receipt of nephrectomy in patients diagnosed RCC in the US. Materials and Methods 2005 to 2015 data from the SEER database was analyzed and 70059 patients with RCC were identified. We compared demographic and tumor characteristics between Blacks and Whites. We applied logistic regression to assess the influence of race on the odds of the receipt of nephrectomy. We also applied Cox proportional hazards model to assess the impact of race on cancer-specific mortality (CSM) and all-cause mortality (ACM) in patients diagnosed with RCC in the US. Results Overall, there was a relative increase in the use of nephrectomy from 2007 (p<0.0001). However, Blacks had 18% lower odds of receiving nephrectomy compared to Whites (p < 0.0001). The odds of the receipt of nephrectomy also reduced with age at diagnosis. In addition, patients with T3 stage had the greatest odds of receiving nephrectomy when compared to T1 (p < 0.0001). There was no difference in the risk of cancer-specific mortality between Blacks and Whites, Blacks had 27% greater odds of all-cause mortality than Whites (p < 0.0001). Patients who did not receive nephrectomy had a 42% and 35% higher risk of CSM and ACM respectively, when compared to patients who received nephrectomy. Conclusions Blacks diagnosed with RCC in the US have a greater ACM risk and are less likely than Whites to receive nephrectomy. Systemic changes are needed to eliminate racial disparity in the treatment and outcomes of RCC in the US.


Introduction
(hypertension, diabetes, and chronic renal failure) and poorer overall cancer survival compared 90 to Whites [12,13]. 91 Studies evaluating disparity in nephrectomy by race have been few and many have yielded 92 equivocal results, necessitating the investigation of the role of race in the receipt of nephrectomy 93 using a large and nationally representative database. Therefore, this study examines the 94 presentation, early definitive surgical treatment, and mortality among patients with RCC in the 95 US, to investigate racial disparity in the receipt of nephrectomy for renal cell carcinoma patients.  Study Population: 105 We identified 75,714 patients diagnosed with histologically confirmed non-metastatic renal cell 106 carcinoma diagnosed between 2005 and 2015. We excluded patients who were diagnosed for the 107 first time in nursing/ convalescent homes (n=242), patients whose race were neither Black nor 108 White (n=5,029) as the size of the patients from other racial groups were small compared to that 109 of Whites or Blacks, and patients diagnosed in Louisiana in 2005 (n=384). The records from . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 2, 2022. "year of diagnosis" and "survival" variables that were operationalized as continuous variables.

128
Outcomes: 129 The unit of analysis was the patient. The primary outcome was the receipt of nephrectomy, 130 which was either radical or partial nephrectomy. CSM (cancer-specific mortality) and ACM (all-. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 2, 2022. ; https://doi.org/10.1101/2022.11.02.22281850 doi: medRxiv preprint cause mortality) were the secondary outcome variables operationalized as time-to-event 132 variables.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted November 2, 2022. ; https://doi.org/10.1101/2022.11.02.22281850 doi: medRxiv preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted November 2, 2022.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted November 2, 2022.  185 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

187
In this study, we investigated the difference in the receipt of nephrectomy and mortality risk 188 between Black and White patients, diagnosed with renal cell carcinoma in the US over ten years.

189
Blacks had lower odds of receipt of nephrectomy and a higher risk of all-cause mortality than 190 Whites. In agreement with our findings, a study by Zini et al. suggests that the receipt of 191 nephrectomy, the gold standard treatment for non-metastatic renal cell cancer, differs by race.

192
However, it suggests that this difference did not have any effect on survival outcomes [15].  The use of nephrectomy appears to be on the rise, and most patients in this study received some 197 form of nephrectomy. Although younger age at diagnosis was associated with greater odds of 198 receipt of nephrectomy and Blacks were more likely to be diagnosed with RCC at a younger age 199 than Whites, Blacks still had 18% lesser odds of nephrectomy receipt than Whites in this study.

200
The SEER programs did not collect information on comorbidity or information that may help to 201 calculate comorbidity scores (e.g., Charlosn Comorbidty Index). Hence the influence of 202 comorbidity on receipt of nephrectomy could not be determined. Previous study examining the 203 influence of age and comorbidity of receipt of radical surgeries for major urological cancers . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted November 2, 2022. ; https://doi.org/10.1101/2022.11.02.22281850 doi: medRxiv preprint Blacks had higher ACM than Whites when diagnosed with renal cell carcinoma in this study.

209
Increasing age at diagnosis, tumor grade, and stage are associated with greater odds of cancer-210 specific and all-cause mortality. Because Blacks have 18% lesser odds of receipt of nephrectomy 211 than Whites, it is not surprising that Blacks have about 27% greater odds of ACM than Whites.

212
Multiple factors such as differential comorbidities and use of other therapies such as adjuvant 213 therapy not captured in this analysis due to the limitation of the data could have affected the 214 ACM outcome. A study that analyzed SEER data concluded that there is reduced receipt of 215 nephrectomy in Blacks versus Whites but suggests that the reduction in receipt of nephrectomy 216 does not influence survival outcomes. The study had a smaller population, a shorter follow-up 217 time and due to its timing, was unlikely to have captured the benefits of nephron-sparing surgery 218 [15].

219
Access to nephrectomy and survival outcomes are lower in Blacks than in Whites [15,18]. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted November 2, 2022. ; https://doi.org/10.1101/2022.11.02.22281850 doi: medRxiv preprint negative predisposition towards the health care system contributes to poorer health outcomes in 232 Blacks diagnosed with RCC.

233
Limitations 234 We applied a retrospective study design. Due to the nature of the SEER data, it was impossible 235 to capture the use of additional therapies such as adjuvant therapies/ chemotherapies which may 236 have effects on survival outcomes. Lastly, information on comorbidities was not available in our 237 data, hence, we were unable to adjust for comorbidities in our analysis.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 2, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted November 2, 2022.